Pressure BioSciences (OTCQB: PBIO) this morning announced
the award of a key new U.S. patent, entitled ”Flow-through High Hydrostatic
Pressure Microfluidic Sample Preparation Device and Related Methods Therefor.”
The company’s creation provides a path for integration of automated
”Hands-Free” sample prep workflows utilizing PBIO’s patented high-pressure
platform technologies. The newly issued patent brings Pressure BioSciences’
Intellectual Property (”IP”) to a total of 21 issued patents. “This
long-anticipated patent is a very important development for the Company on
multiple fronts, and the timing of its issuance could not be better. This
invention covers key elements of our plans for developing automated,
”hands-free” sample handling for the next generation of our high-pressure
sample preparation platform technologies. This invention also enables a unique
capability for maintaining high pressure in a flow-through format (rather than
current batch processing), which we expect will facilitate the development of
new, automated continuous process monitoring tools applicable to diverse segments
of the life sciences industry. Finally, we believe this novel flow-through
concept offers critical enablement for future system design strategies for
epitope characterization, an emerging area in development and production of
biotherapeutics that could revolutionize personalized therapy for numerous
medical conditions, including autoimmune diseases and a variety of rare medical
disorders,” Pressure BioSciences Vice President of Research and Development Dr.
Alexander Lazarev stated in the news release.
To view the full press release, visit http://ibn.fm/BGz9p
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. Our products are based on the unique
properties of both constant (i.e., static) and alternating (i.e., pressure
cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling
technology platform that uses alternating cycles of hydrostatic pressure
between ambient and ultra-high levels to safely and reproducibly control
bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our
primary focus is in the development of PCT-based products for biomarker and
target discovery, drug design and development, biotherapeutics characterization
and quality control, soil & plant biology, forensics, and counter-bioterror
applications. Additionally, major new market opportunities have emerged in the
use of our pressure-based technologies in the following areas: (1) the use of
our recently acquired PreEMT technology from BaroFold, Inc. to allow entry into
the biologics contract research services sector, and (2) the use of our recently-patented,
scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”)
platform to (i) create stable nanoemulsions of otherwise immiscible fluids
(e.g., oils and water) and to (ii) prepare higher quality, homogenized,
extended shelf-life or room temperature stable low-acid liquid foods that
cannot be effectively preserved using existing non-thermal technologies. For
more information, visit the company’s website at www.PressureBiosciences.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
